Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769884 | 1.00 | TSHR (0.37) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL16901709 | 0.85 | EGFR (0.35) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL14165950 | 0.83 | CCNK (0.34) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL14165949 | 0.83 | CCNK (0.34) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL23158239 | 0.82 | — | — | |
| SCHEMBL15786501 | 0.82 | — | — | |
| SCHEMBL15783538 | 0.81 | — | — | |
| SCHEMBL24447200 | 0.79 | ALDH1A1 (0.30) | TSHR | |
| SCHEMBL23178902 | 0.78 | — | — | |
| SCHEMBL18557449 | 0.75 | DPP4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249950-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4056562-A1 | HETEROCYCLIC INHIBITORS OF BRUTON'S TYROSINE KINASE | Merck Patent GmbH (DE) | 2022-09-14 | — | — | EP | disclosed |
| EP-2718270-B1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-10413562-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2019-09-17 | — | — | US | disclosed |
| US-20180243324-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-9580449-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20150259363-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-9073947-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | TSHR 1964/4885GABRR1 4448/4885GABRR2 4613/4885 |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | TSHR 1964/4885GABRR1 4448/4885GABRR2 4613/4885 |
| US-20180243324-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | TSHR 1964/4885GABRR1 4448/4885GABRR2 4613/4885 |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | TSHR 4685/4885GABRR1 4336/4885GABRR2 4348/4885 |
| US-10413562-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | TSHR 1964/4885GABRR1 4448/4885GABRR2 4613/4885 |
| US-20150259363-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | TSHR 1964/4885GABRR1 4448/4885GABRR2 4613/4885 |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | TSHR 1964/4885GABRR1 4448/4885GABRR2 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.